Infliximab Therapy Improves Health Related Quality of Life in Ulcerative Colitis Patients

Feagan, Brian G.; Rutgeerts, Paul; Hanauer, Stephen B.; Yan, Suxia; Eisenberg, D.; Johanns, Jewel; Olson, Adriana Segura; Sandborn, William J.

doi:10.14309/00000434-200509001-00792

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The measurement of quality of life in clinical trials in patients with UC has been limited to date. 25,40,98 The instruments used to measure quality of life include the SF-36 and the IBDQ. In Crohn's disease, the end points based on the IBDQ for quality of life response and normal quality of life (consistent with clinical remission) in individual patients are a change of 16 points and an absolute score of 170 points, respectively.…”

Section: Quality Of Lifementioning

confidence: 99%

A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis

et al. 2007

View full text Add to dashboard Cite

Section: Quality Of Lifementioning

confidence: 99%

A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis

et al. 2007

View full text Add to dashboard Cite

“…For fistulizing CD, infliximab therapy increases all dimensions of the IBDQ score, with significant changes in systemic, emotional, and social components seen as early as 2 weeks after initiation of therapy [29]. In UC patients, infliximab treatment results in substantially improved HRQOL as measured by all four dimensions of the IBDQ and all eight scales of the SF-36 [30]. Special points Infliximab, similar to other biologic agents, is an immunogenic molecule, which may be due in part to its chimeric human-murine composition.…”

Section: Standard Dosing Regimenmentioning

confidence: 99%

Pharmacoeconomics and quality of life of current and emerging biologic therapies for inflammatory bowel disease

Zisman¹,

Cohen

2007

Curr Treat Options Gastro

View full text Add to dashboard Cite

The development of biologic therapies for Crohn's disease and ulcerative colitis has profoundly affected the treatment of these diseases. The impact of these novel therapies has been tremendous in terms of their ability to cause clinical improvement in symptoms and endoscopic and histologic evidence of healing, as well as improvements in quality of life. However, the success of these new remedies comes with a significant price tag. In the current cost-containment environment of health care, it is essential to evaluate the impact of these novel and promising therapies on health care resource utilization, employment productivity, and quality of life. Despite the high cost of these new medications, they may result in a net cost savings through their ability to induce remission in the sickest of inflammatory bowel disease (IBD) patients, thereby averting the large expenditures associated with hospitalization and surgery. Likewise, by improving patients' physical symptoms, emotional well-being, and quality of life, biologic agents have the potential to reduce much of the unemployment, missed work, and disability through which IBD patients suffer. In a disease with an early age of onset and a chronic course with normal life expectancy, reducing morbidity and improving quality of life should be important measures of treatment success. Biologic therapies for IBD hold significant promise in this regard, allowing clinicians to achieve lasting remission in patients who are unresponsive to conventional therapies. Comparison of the costs and benefits of biologic therapies with conventional treatments for IBD is complicated by the need to assess the downstream effects of an intervention. For example, corticosteroids are inexpensive and very effective for induction of remission, but they come with significant long-term complications, such as osteoporosis, cataracts, impaired glucose tolerance, and poor wound healing, which must be taken into account when assessing their true cost as a maintenance medication. We do not yet have enough experience with biologic therapies to evaluate their potential to prevent or create future costs associated with adverse effects. However, as we move forward with our knowledge of biologic agents, an understanding of the economic and quality-of-life implications of these innovative therapies is crucial for patients, clinicians, and third-party payers alike.

show abstract

Infliximab Therapy Improves Health Related Quality of Life in Ulcerative Colitis Patients

Cited by 2 publications

References 0 publications

A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis

A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis

Pharmacoeconomics and quality of life of current and emerging biologic therapies for inflammatory bowel disease

Contact Info

Product

Resources

About